Clinical trial
PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)
NCT05949593 is registered in ClinicalTrials.gov with Belite Bio, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)
- Lead sponsor
- Belite Bio, Inc
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- July 27, 2023
- Completion date
- August 31, 2027
- Enrollment
- 429 (estimated)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.